
Hepatitis C treatment and follow up – challenges in Albania


Jovan BASHO

Service of Hepatology/Gastroenterology UHC "Mother Tereza", TIRANA

HCV infection: Global prevalence



Increased Morbidity and Mortality Due to HCV Now and in the Future




persons to care and successful treatment are needed.


DCC, decompensated cirrhosis Adapted from Ly KN et al. Ann Intern Med. 2012;156:271-278. Adapted from Rein DB et al. Dig Liver Dis. 2011;43:66-72.

Year

Mortality and Morbidity Reduced with SVR


- 530 adults in Europe prospectively followed for median 8.4 years after HCV treatment
- 192 (36%) achieved SVR







Hepatitis C: beyond the liver....



Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology. 2015;149:1345-60

Utility of HCV Virological Tools


- 1. Diagnosis of HCV infection
- 2. Decision to treat
- 3. Choice of optimal therapy
- 4. Monitoring of virological response

1. Diagnosis of HCV infection

- a. Anti HCV positive:
 - ALT
 - HCV RNA
 - Genotype HCV
 - biopsy of the liver,
 - or fibroscan,
 - or fibrotest

2. Decision to treat

- a. Treat all patients (impossible for Albania)
- b. Treat selected patients
 Albania in 2015: 1. patients F3 F4 (g.1)
 2. patients with cryoglobulinemia
 Proposition for 2017:
 - 1. Treat all patients \geq F3 (all genotypes)
 - 2. Special groups:
 - pts with co-infection HIV or HCV
 - pts with an indication for organ transplantation
 - pts with clinically significant extra-hepatic manifestation



3. Choice of optimal therapy (1)

Drug in reimbursement list (Albania 2016)


- 1. Pegylated INF alfa 2 a/b + Ribavirin
- 2. Sofosbuvir + Pegylated INF alfa 2 a/b + Ribavirin
- 3. Sofosbuvir + Ledipasvir (Harvoni)
- 4. Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir

3. Choice of optimal therapy (2)

Treatment with Pegylated INF alfa 2 a/b + Ribavirin

More than 350 pts were treated or are under the treatment (last three yrs.).

(Service of Hepatology/Gastroenterology UHC, Tirana)



3. Choice of optimal therapy (3)

Treatment with DAAs in Albania (48 pts)

- Sofosbuvir + Pegylated INF alfa 2 a + Ribavirin
 - 13 pts were treated (12 weeks). 11/13 HCV RNA was negative after 24 weeks of follow-up (relapse in two pts treated with Sofo + RIBA)
 - 15 pts are under the treatment (HCV RNA week 4, negative in all)
 - 9 pts are approved and waiting for treatment
- 2. Sofosbuvir + Ledipasvir (Harvoni)

9 pts were treated (12 weeks) waiting for HCV RNA after 24 weeks - 2 pts are under the treatment

 Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir

- 10 pts were treated (12 weeks) waiting for HCV RNA after 24 weeks

4. Monitoring of virological response (1)

-Protocol for which type of treatment:

Combined treatment: Peg INF + RIBA


 Monitor HCV RNA during treatment
 (weeks 4, 12, 24, w 24 during FU)
 Early diagnosis of side effects and
 treatment of them in time.

4. Monitoring of virological response (2)

-Protocol for which type of treatment:

 DAAs with or without RIBA HCV RNA during the treatment (week 4, 8, w 24 of FU) Need to treat early/possibilities to treat


The value of liver stiffness measurement predicts survival in HCV patients



Vergniol J, et al. Hepatology 2014;60:65-7


We need to treat more patients

- a. All DAAs are effective
- b. Optimisation of therapy



Choose the best treatment for our patients a. Naïve pts G1


Sofosbuvir/ledipasvir ± RBV for 8 weeks vs 12 weeks in treatment-naive non-cirrhotic G1 HCV-infected patients



8 weeks without RBV not statistically inferior
 Without cirrhosis 8 weeks is the right duration

Choose the best treatment for our patients b. Experienced pts

TURQUOISE-II: SVR12 rates in GT1 treatment-naive and experienced cirrhotic patients by HCV genotype



Poordad F, et al. N Engl J Med 2014. Online DOI:10.1056/NEJMoa1402869.

Conclusions

- HCV is an curable disease
- For many countries: Peg INF + RIBA
- DAAs
 - Not for all pts (in our country).
 - Optimisation of treatment (Need to treat more pts)
 - Viral resistance (a problem for the future)
 - Know HCV RNA in distance after treatment

